IL6R and melanoma: To evaluate whether this enhanced IL-6 signaling mediated JAK1/2 activation, we blocked IL-6 and IL-6R with anti-IL-6 and anti-IL-6R antibodies, respectively, at concentrations that were sufficient to inhibit IL-6-induced p-STAT3 in melanoma cells (Supplementary Fig. 4a).